{"id":"NCT01568593","sponsor":"Laboratoires Thea","briefTitle":"Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome","officialTitle":"Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2012-04-02","resultsPosted":"2014-10-27","lastUpdate":"2016-04-04"},"enrollment":93,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndromes"],"interventions":[{"type":"DEVICE","name":"T2750","otherNames":[]},{"type":"DEVICE","name":"Vismed","otherNames":[]}],"arms":[{"label":"T2750","type":"EXPERIMENTAL"},{"label":"Vismed","type":"ACTIVE_COMPARATOR"}],"summary":"Comparison of the efficacy and safety of T2750 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome","primaryOutcome":{"measure":"Global Ocular Staining (With Oxford Scale - Ranges :0-15)","timeFrame":"Baseline and 35 days","effectByArm":[{"arm":"T2750","deltaMin":-1.8,"sd":2.2},{"arm":"Vismed","deltaMin":-2,"sd":1.4}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":1,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":48},"commonTop":[]}}